Israeli researchers find more than a fivefold risk of developing systemic sclerosis among people with vitiligo.
Research has shown that patients with vitiligo are disproportionately affected by a variety of other autoimmune diseases, including rheumatoid arthritis, alopecia areata and lupus erythematosus.
But less is known about the relationship between vitiligo and systemic sclerosis, a rare chronic condition that involves the buildup of scar tissue in the skin, joints and internal organs. Systemic sclerosis can result in pigment changes in the skin, including a loss of pigment that resembles vitiligo and a combination of loss and gain of pigment that causes a salt-and-pepper appearance.
A team of Israeli researchers led by Khalaf Kridin, M.D., Ph.D., used the database of Clalit Health Service, the largest HMO in Israel, to examine the relationship between vitiligo and systemic sclerosis. They identified close to 21,000 people in the database with vitiligo and a little over 100,000 who could serve as age-, sex- and ethnicity-matched control.
They reported their results in the Australian Journal of Dermatology earlier this month.
They found that the risk of developing systemic sclerosis was five times higher among the patients with vitiligo than the matched controls. The incidence rate of systemic sclerosis was 2.4 cases per 10,000 person-years among patients with vitiligo. Among the controls, it was 0.4 cases of 10,000 person-years.
In a smaller group of patients, Kridin and colleagues also looked at the risk of vitiligo among those a history of systemic sclerosis. After variety of statistical adjustments, they found that the risk of vitiligo was twice as high among people with systemic sclerosis.
Reasons for the association between vitiligo and systemic sclerosis were beyond the scope of this epidemiologic study, but Kridin and his colleagues shared some theories. Fibroblasts, the cells that product collagen and play a role in systemic sclerosis, affect pigmentation and therefore may play a causal role in vitiligo. Another possibility is that the autoimmune processes that cause vitiligo also play a role in causing systemic sclerosis.
Joseph Zabinski Advocates for Patient Trust in AI Adoption in Dermatology Care
April 18th 2024Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, chatted with MHE editors on the significance of patient acceptance in AI adoption in healthcare, overall and in the dermatology space, stressing trust and transparency.
Read More
Microneedling Combined with Other Vitiligo Therapies Offers Promising Treatment for Skin Disease
April 10th 2024Researchers of a study conducted a double-blind intervention that aimed to assess the effectiveness and tolerance of a new approach for vitiligo treatment using meso-microneedling with 5% N-acetylcysteine (NAC) ampoules and topical 4.7% NAC, compared to microneedling alone.
Read More
Positive Results for Ruxolitinib Cream in Children with Atopic Dermatitis Presented in Ongoing Study
March 18th 2024Ruxolitinib cream showed positive results in children 2- to 11-years-old with mild to moderate atopic dermatitis (AD), according to data of a poster presented at the American Academy of Dermatology Annual Meeting in San Diego from March 8 to 12.
Read More
Opzelura Provides Benefit in Atopic Dermatitis in Real-World Studies | AAD 2024
March 8th 2024Physicians switch to Opzelura (ruxolitinib) when other therapies fail to help patients with atopic dermatitis, according to a new analysis presented at the annual meeting of the American Academy of Dermatology.
Read More